| Catalog No. | DF879028 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 329.66 ng/mL |
|---|
| Range | 468.75 - 30,000 ng/mL |
|---|
| Accession | P01375 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃. |
|---|
| Specifications | Certolizumab |
|---|
| Alternate Names | CDP870, PHA-738144, Certolizumab pegol, CAS: 428863-50-7 |
|---|
| Background | Certolizumab pegol is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It does not contain an FC region and therefore does not cause antibody-dependent cell-mediated or complement-dependent cytotoxicity as described for infliximab, etanercept, and adalimumab. Another difference is that certolizumab pegol preferentially penetrates inflamed tissue compared to noninflamed tissue, and does so to a greater extent than adalimumab or infliximab. It is directed against soluble and membrane-associated human TNF-α and was approved for the treatment of Crohn’s disease that does not respond to conventional therapy in 2008 and for RA in 2009. |
|---|
| Note | For Research Use Only. |
|---|
